XiaoMi-AI文件搜索系统
World File Search SystemSubjects
以下是一些支持在家学习的网站。该列表并不详尽，还有其他网站可供选择，这些网站的主题可能
以下是一些支持在家学习的网站。此列表并不详尽，其他科目可能已经使用过的网站也可用。https://studyrocket.co.uk/ Study Rocket 可帮助您从 AQA、Edexcel、OCR 中找到正确的复习内容。只需从数千个免费的 A-level 和 GCSE 课程中进行选择即可。https://app.senecalearning.com/courses?Price=Free 帮助 2,500,000 多名学生更快地学习和更好地记忆。我们的家庭作业和复习平台应用认知神经科学，使学习更高效、更愉快。https://getrevising.co.uk/ Get Revising 可以帮助您备考。功能包括独特的复习时间表创建器、交互式复习 https://www.s-cool.co.uk/ 为学生提供免费复习网站，提供复习指南、题库、复习时间表等 https://quizlet.com/ 为学生提供分享学习笔记和抽认卡的出色社区网站 https://www.khanacademy.org/signup 数学、科学、经济学、计算机编程和历史的视频教程和测试 https//www.sparknotes.com/ 探索英国文学文本，观看视频摘要，并学习许多其他科目 https://www.sparknotes.com/shakespeare 将原始文本与现代翻译并排放置，帮助您了解故事并随时翻译新单词。 http://www.bbc.co.uk/scotland/brainsmart/success/ 需要快速学习休息一下？为什么不通过玩 BBC Brain Smart 的游戏来保持高效并唤醒您的大脑呢。
主题说明表格
学生进行功能解剖学课程已经具有基本的解剖学知识。在学科完成后，学生将能够证明对人体结构的理解，并将解剖学知识应用于人体的功能观点。系统将被覆盖为外皮，骨骼，肌肉，关节，神经，心脏血管，呼吸，特殊感觉和淋巴。重点包括解剖学术语和描述性术语，骨骼的排列，骨骼的总体结构和分类，关节和肌肉的分类和功能以及神经和血管。随后进行了上述结构的区域研究。学习活动包括独立和小组研究。讲座和实验室会议，包括各种教育媒体（例如，骨骼，尸体实行，模型，参考材料，多媒体自学习套件）用于增强学习。此外，学生将有机会以一小组形式向同龄人传授一小部分解剖结构。通过讲师，独立和/或小组研究来学习其余的实验室材料。
Dayalbagh教育学院（视为...
1。书面目标测试的结构3 2。高中级7-一般科学，化学，物理，数学，服装技术3。Intermediate level - Science subjects 17 (Botany, Chemistry, Mathematics, Physics and Zoology) - Commerce subjects 29 - Arts subjects 29 (Drawing & Painting, Fine Arts (BFA), Economics, English, Hindi, Home Science, Music (Sitar/Vocal), Music (Tabla),Political Science (Civics), Psychology, Sanskrit and Sociology) - Modern Office Management & Secretarial Practice 38 -B.Tech。（兼职）电气38- b.voc。39乳制品/水，卫生与废物管理/农业技术/物品互联网/汽车/可再生能源/银行和金融/ AI/ AI和机器人和数字制造/远程策略/远程信息处理/ Greenhouse/ Accounting/ Accounting and Taxation和税收
入学印度 - 工程
Qualifying Examination: Applicant should have passed in Higher secondary examination (10, +2 pattern) or appearing in Higher Secondary examination in the current academic year with a minimum of 60% aggregate ( 3 subjects) in Physics (mandatory) , Mathematics (mandatory) and at least one of Chemistry / Biotechnology / Biology / Computer Science / Information Technology / Informatics Practices / Engineering Graphics / Botany and Zoology as major subjects in regular stream from印度内的任何董事会，CBSE，ISCE，IB或NIOS*。
实验室培训清单 - 微生物感染与免疫力
HUMAN SUBJECTS TRAINING (OPTIONAL) orrp.osu.edu/irb TRAINEE DATE COMPLETED I have completed the Human Subjects Protection – HSP (CITI) I have completed the Good Clinical Practice – GCP (CITI, if applicable) I have completed the US Export Control Regulation Course (CITI, if applicable) LAB SPECIFIC CHEMICAL/PROCEDURAL SOPs TRAINEE DATE COMPLETED I have read the lab specific SOPs listed below (on shelf across from 761）☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
在早产与完整学科的多尺度大脑网络之间改变了功能网络能量：青少年脑认知发展（ABCD）研究
摘要 - 婴儿过早出生或早产，可能会改变大脑的连接性，部分原因是分娩时的大脑发育不完整。研究还显示，与出生时完全成熟的同龄人相比，这些人进入青春期时，大脑的结构和功能差异。在这项研究中，我们研究了来自青少年脑认知发展（ABCD）研究的大约4600名青少年的多尺度功能连通性的功能网络能量，他们是早产或出生时的全学期。我们确定了三个关键的大脑网络，它们在早产和成熟受试者之间显示网络能量的显着差异。这些网络包括视觉网络（包括枕骨和枕骨子网），感觉运动网络以及高认知网络（包括颞叶和额叶子网）。此外，已经证明，与早产受试者相比，完善受试者表现出更大的不稳定性，从而导致功能性脑信息的动态重新配置更大，并在三个确定的规范大脑网络中提高了灵活性。相比之下，那些天生的过早表现出更稳定的网络，但在这些关键规范网络中功能性大脑信息的动态和灵活组织较少。总而言之，测量多尺度功能网络能量提供了对与出生的受试者相关的规范大脑网络的稳定性的见解。这些发现增强了我们对早期出生如何影响大脑发育的理解。索引术语 - 早产学科，完整学科，多尺度功能连接，功能网络能量，大脑发展
FT-002的试点基因治疗研究的初步安全性和功效引起的RPGR基因突变相关的X连锁性视网膜炎
疾病背景：X连锁性视网膜炎色素（XLRP）是一种严重的RP形式，其特征是夜失明，视力降低，外围视野的进行性恶化，并在40多岁后最终成为法律上的盲人。色素炎的变体GTPase调节剂（RPGR）基因占XLRP的70％以上，所有RPS的病例约为15％。RPGR ORF15的突变会导致RPGR ORF15蛋白质的截断以及其功能的损害或损失，从而导致OPSIN对光感受器内部节段或内质网的错误定位，这反过来会导致光感受器细胞的失败至关重要。RPGR-XLRP患者的患病率估计为男性为3.4-4.4/100,000，在美国和欧洲估计有20,000名患者，在中国有50,000名患者。
761055orig1s000 -AccessData.fda.gov
表32。Schedule of Events - Screening, Baseline, and Treatment Period – Visits 1 through 14* ......................................................................................................................................................87 Table 33.事件时间表 - 治疗期限续。- 访问15至27* .........................................................................................................................................................................................................................................................................................................................................................................................................................................................活动时间表 - 后续行动，外观访问和提前终止*............................................................................................................................................................................................................................. 91表35。Initial (16-week) Treatment Period Subject Disposition for Trial 1224*.......................95 Table 36.Summary of Subject Accountability and Study Disposition – All Randomized Subjects* ......................................................................................................................................................96 Table 37.Summary of Major Protocol Deviations – All Randomized Patients*...........................98 Table 38.Baseline Demographics for Trial 1224* ........................................................................99 Table 39.Baseline Disease Severity for Trial 1224* ...................................................................100 Table 40.Medical History Findings (≥5% of Patients in Any Treatment Group) by Primary System Organ Class and Preferred Term– SAF*......................................................................................101 Table 41.Atopic/Allergic Disease History – SAF* .......................................................................102 Table 42.Compliance with Background Moisturizer (Emollient)* .............................................103 Table 43.Rescue Medication Taken during the 16-Week Period – SAF*...................................105 Table 44.Rescue Medication Taken during the 52-Week Period*.............................................106 Table 45.在第16周联合试验中获得治疗成功的受试者的比例1224*.......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................在第16周* ...............................................................................................................................................................................................................从基线到第16周的峰值每日瘙痒率≥4的每周峰值平均每周平均每周的受试者比例（减少）*...............................................................................................................................................................................................................Proportion of Subjects with at least 4-point change from baseline Weeks 2, 4, 16 for Trial 1224*..................................................................................................................................109 Table 49.Proportion of Subjects with IGA success(1) at Week 52 among those that were IGA responders(1) at Week 16 for Trial 1224*..................................................................................109 Table 50.Success on the IGA at Week 16 by Baseline IGA Severity for Trial 1224*...................110 Table 51.在研究第16周实现治疗成功的受试者的比例1224*... 112表55。效力（IgA 0或1）通过基线人口统计学研究1334和1416*..................................................................................................................................... 113表56。Proportion of Subjects Achieving Treatment Success at Week 16 for Monotherapy Studies 1334, 1416* ...................................................................................................................111 Table 52.Proportion of Subjects Achieving Treatment Success at Week 16 for Combination Study 1224*................................................................................................................................111 Table 53.Proportion of Subjects Achieving Treatment Success at Week 16 for Monotherapy Studies 1334, 1416* ...................................................................................................................112 Table 54.效力（IgA 0或1）通过基线人口统计学的试验1224*。IgA响应者由基线IgA严重程度1334和1416*........................................................................................................................................................................................................................................................................................................................................................................................................................................................... 114表58。研究在第16周的IGA成功，基线IgA严重程度研究1224*.............................................................................................................................................................................................................................................................................................................................................................................................................................................Efficacy Results of DUPIXENT Monotherapy at Week 16 (FAS) ..................................119 Table 60.Efficacy Results of DUPIXENT with Concomitant TCS a at Week 16.............................120 Table 61.按研究编号按样本量 - 初级安全池 - （所有注册受试者）*......... 123
附件6
7.1 Design of pharmacokinetic studies 194 7.1.1 Alternative study designs for studies in patients 195 7.1.2 Considerations for active pharmaceutical ingredients with long elimination half-lives 195 7.1.3 Considerations for multiple-dose studies 195 7.1.4 Considerations for modified-release products 196 7.2 Subjects 197 7.2.1 Number of subjects 197 7.2.2 Drop-outs and withdrawals 198 7.2.3 Exclusion of subject data 198 7.2.4 Selection of subjects 198 7.2.5 Monitoring the health of subjects during the study 199 7.2.6 Considerations for genetic phenotyping 199 7.3 Investigational product 200 7.3.1 Multisource pharmaceutical product 200 7.3.2 Choice of comparator product 200 7.4 Study conduct 201 7.4.1 Selection of strength 201 7.4.1.1 Non-linear pharmacokinetics 201 7.4.2 Study standardization 201 7.4.3 Co-administration of food and fluid with the dose 202 7.4.3.1即时释放配方202 7.4.3.2修改的释放配方202 7.4.4洗涤间隔203 7.4.5抽样时间203 7.4.6样品液体及其集合204 7.4.7要评估的参数204 7.4.4代谢物研究205 7.4.9统计7.5量化6.5量子206 7. 6 7. 6 7. 6 7. 6 7. 6 7. 6 7. 6 7. 5量子。两阶段顺序设计210 7.7接受范围211 7.8结果报告211 7.9特殊考虑212 7.9.1固定剂量组合产品212 7.9.2生物利用性临床上重要的生物利用性变化213 7.9.3“高度可变的活性药物药物成分” 213
ASHG 2023海报摘要
PB 1003 A biobank catalogue of transcriptomes and associated genetic effects based on 2,000 subjects uncovers the causal effects of Middle Eastern genetic variation and uncovers novel disease mechanisms .............................................................................................................................................................. 142